Clinical trial · Interventional
MRD-positive AML Clinical Study
MRD-positive AML: a Prospective, Single-arm, Multicenter Platform Clinical Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This clinical trial is a platform-type clinical study intended to investigate the efficacy and safety of MRD-positive acute myeloid leukemia patients after comprehensive treatment, which includes but is not limited to the following drugs and protocols: Chemotherapy, small molecule targeted drugs, demethylation drugs, liposome drugs and the combination of these drugs to form a combination of treatment regimen, the specific treatment regimen will be updated according to the results of this trial and the latest research progress at home and abroad.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| AML, Adult | Adult Acute Myeloid Leukemia | ALIAS | 0.90 |
Interventions
Interventions (12)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Avapritinib | Drug | Avapritinib | ALIAS |
| Azacitidine | Drug | Azacitidine | ALIAS |
| Cytarabine | Drug | Cytarabine | ALIAS |
| Daunorubicin | Drug | Daunorubicin | ALIAS |
| Gilteritinib | Drug | Gilteritinib | ALIAS |
| Homoharringtonine | Drug | Omacetaxine Mepesuccinate | ALIAS |
| Idarubicin | Drug | Idarubicin | ALIAS |
| Ivosidenib | Drug | Ivosidenib | ALIAS |
Design
Arms and outcomes
Arms (9)
- type
- EXPERIMENTAL
- label
- With lDH1 gene mutation
- description
- Ivosidenib 500mg/d: d1-28 ；Azacitidine 75mg/m2/d: d1-7；Venetoclax 600mg/d: d1-14
- interventionNames
- Drug: Ivosidenib
- Drug: Venetoclax
- Drug: Azacitidine
- type
- EXPERIMENTAL
- label
- FLT3 gene mutation
- description
- Gilteritinilb 120mg/d: d1-28； Venetocax 400mg/d: d1-7；Azacitidine 75mg/m2/d : d1-7
- interventionNames
- Drug: Gilteritinib
- Drug: Venetoclax
- Drug: Azacitidine
- type
- EXPERIMENTAL
- label
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 14 Years
Show eligibility criteria text
Inclusion Criteria: * AML (non-M3) compliant with WHO (2016) standards; * In morphological complete remission. * Mrd-positive patients: including bone marrow flow cytometry, PCR quantification of NPM1 mutations, PCR quantification of fusion genes (RUNX 1-RUNX1T1, CBFB-MYH11 and DEK-NUP214), or NGS detection of FLT3 mutation positive. * Age over 14 years old, male or female. Informed consent must be signed prior to the commencement of all specific study procedures, and for those 14 years of age and older, informed consent must be signed by the patient or an immediate family member. Considering the patient's condition, if the patient's signature is not conducive to the treatment of the condition, the informed consent shall be signed by the legal guardian or the patient's immediate family. Exclusion Criteria: * Patients who intend to undergo hematopoietic stem cell transplantation within 4 weeks * The diagnosis is APL * Those who were not considered suitable for inclusion by the researchers.
References
Publications (0)
Data not yet available